New Oral Cancer Drug Data to Be Presented in October
Initial trial results for the experimental drug ISM6331 will be shared with the medical community at an upcoming conference.
Updated on Sept. 22, 2026 in Cancer
Live Poll
Will AI-designed medicines significantly reduce the time required to bring new treatments to patients?
Researchers will present Phase I clinical trial data for the investigational drug ISM6331 on October 25, 2026, at the ESMO Congress in Madrid. The oral medication is currently under study for the treatment of patients with advanced solid tumors.
Why it matters
ISM6331 aims to treat cancers by disrupting tumor-promoting signals linked to the Hippo pathway, a biological mechanism involved in cell growth and regulation. This upcoming presentation follows the drug receiving Fast Track Designation from the FDA in July 2026.
The Phase I clinical trial evaluates the safety and tolerability of the oral small-molecule inhibitor in patients with advanced solid tumors. Results are currently being prepared for initial presentation following the study's initiation in January 2025.
The players
Insilico Medicine
A biotechnology company focused on using artificial intelligence and generative biology for drug discovery and development.
FDA
The federal agency responsible for regulating pharmaceuticals and overseeing clinical development pathways.
The details
ISM6331 functions as a pan-TEAD inhibitor, a class of drugs that targets and disrupts the Hippo signaling pathway. By blocking these signals, the therapy is intended to interrupt the pathways that drive tumor growth. The molecule was specifically designed using the Chemistry42 generative chemistry platform.
Timeline
June 2023: ISM6331 was nominated as a preclinical candidate.
June 2024: The FDA granted the drug Orphan Drug Designation.
January 2025: The Phase I clinical trial was officially initiated.
July 2026: The FDA granted the drug Fast Track Designation.
October 25, 2026: Initial Phase I clinical data will be presented in Madrid.
Health Landscape
The development of ISM6331 aligns with a growing industry effort to target the Hippo signaling pathway in oncology. This therapeutic approach aims to address tumors that rely on specific dysregulated pathways to fuel their growth and progression.
Patients with advanced solid tumors who may be eligible for clinical trials should discuss the status of new, targeted therapies like ISM6331 with their oncologists. Staying informed about drug designations such as Fast Track or Orphan status can provide insight into ongoing research and potential treatment timelines.
The takeaway
ISM6331 is an experimental oral inhibitor designed to block tumor growth signaling, with early safety results expected this October. Patients interested in how targeted research may impact future care options should consult with their physician about clinical trial availability for their specific diagnosis.
Further reading
For more on the current development landscape of novel oncology treatments, visit our Cancer section.
More information
View the Phase I clinical trial details on the official government registry.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Will AI-designed medicines significantly reduce the time required to bring new treatments to patients?
